Cancer Therapy : Preclinical PRAME-Specific Allo-HLA – Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer

@inproceedings{Amir2011CancerT,
  title={Cancer Therapy : Preclinical PRAME-Specific Allo-HLA – Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer},
  author={Avital L. Amir and Dirk M. van der Steen and Marleen M. van Loenen and Renate S. Hagedoorn and Renate de Boer and Michel G. D. Kester and Arnoud H. de Ru and Gert-Jan Lugthart and Cees van Kooten and Pieter S Hiemstra and Inge Jedema and Marieke Griffioen and Peter A. van Veelen and J H Frederik Falkenburg and Mirjam H M Heemskerk},
  year={2011}
}
Purpose: In human leukocyte antigen (HLA)–matched stem cell transplantation (SCT), it has been shown that beneficial immune response mediating graft-versus-tumor (GVT) responses can be separated from graft-versus-host disease (GVHD) immune responses. In this study, we investigated whether it would be possible to dissect the beneficial immune response of allo-HLA–reactive T cells with potent antitumor reactivity fromGVHD-inducing T cells present in the detrimental immune response after HLA… CONTINUE READING